NCT03173235 is a clinical trial of Plasma level of vitamin D in Infertility, Female, sponsored by University Hospital Tuebingen.

Who is sponsoring NCT03173235?

NCT03173235 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03173235?

Interventions in NCT03173235: Plasma level of vitamin D.

What condition does NCT03173235 study?

NCT03173235 studies Infertility, Female.

Is NCT03173235 still recruiting?

NCT03173235 is currently completed. Last updated 22 January 2025.

Last reviewed 2025-01-22 · How we verify

NCT03173235

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma Concentrations of Calcium, Phosphate, FGF23, Klotho, 25 (OH) D3 and 1,25 (OH) 2D3 from Patients Who Wants to Have Children

Completed Last updated 22 January 2025

What this trial tests

trial testing Plasma level of vitamin D in Infertility, Female in 80 participants. Completed in 1 December 2021.

Timeline

1 August 2015

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	University Hospital Tuebingen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	1 August 2015
Primary completion	1 December 2021
Estimated completion	1 December 2021
Sites	1 location across Germany

Drugs / interventions tested

Plasma level of vitamin D

Conditions studied

Infertility, Female — all drugs for Infertility, Female →

Sponsor

University Hospital Tuebingen

Who can join

Adults 18 to 45, female only, with Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1,25-dihydroxy-vitamin D3 (1,25 (OH) 2D3) or calcitriol regulates plasma calcium and phosphate concentrations in the blood by stimulating intestinal absorption and renal reabsorption of calcium and phosphate. 1.25 (OH) 2D3 is formed by the renal 1α25OH vitamin D-hydroxylase (Cyp27b1) and inactivated by the renal 25-hydroxy vitamin D-24-hydroxylase (Cyp24). Unpublished studies in mice revealed an inhibitory effect of 1.25 (OH) 2D3 on embryo implanation. An excess of 1.25 (OH) 2D3 could therefore lead to female infertility. The excess of 1.25 (OH) 2D3 could result from uncritical vitamin D intake with insufficient negative feedback by FGF23 / Klotho. The aim of the study is to identify patients with an excess of 1.25 (OH) 2D3.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Infertility, Female

Currently open trials in the same condition.

NCT06771401 — Identification of Biomarkers in Cervical Mucus · NA · recruiting
NCT06984081 — CAPA In-vitro Oocyte Maturation · NA · recruiting
NCT07308561 — The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Under · recruiting
NCT07175571 — SISTER: Sibling Oocyte Insemination With Frozen Sperm From Third Party Donors: Evaluation of Reproductive Techniques · NA · recruiting
NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03173235 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 22 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03173235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing